Jeeva Clinical Trials Acquires AI Platform Clintelligence to Streamline Trial Design

by SAH Staff Reporter May 12, 2026

By SAH Staff Reporter May 12, 2026 0 comments 3 minutes read

Courtesy: Presswire

Jeeva Clinical Trials, a leader in decentralized and hybrid clinical trial technology, announced on May 12 the acquisition of Clintelligence, an “AI-powered clinical trial intelligence platform that analyzes insights from over one million historical studies.”

According to a statement issued through Presswire, the acquisition significantly expands Jeeva’s Unified AI-Ready Clinical Platform by adding an intelligence-driven layer at the earliest stages of clinical development, a phase often critical to determining trial success or failure.

With the integration of Clintelligence into Jeeva’s platform, sponsors will be able to “design, optimize, and execute clinical trials” within a single connected system, spanning protocol development through “patient enrollment, data capture, and study completion.”

“The biggest inefficiencies in clinical trials are not just operational, they are foundational,” said Harsha K. Rajasimha. “Protocol complexity and suboptimal design remain the leading drivers of delays, amendments, and trial failures. Clintelligence brings predictive intelligence to the front of the lifecycle, enabling sponsors to identify risks early, optimize design, and move forward with confidence. This is a transformative step toward faster, smarter, and more patient-centric trials.”

The statement noted that clinical development continues to face significant inefficiencies across the industry. Data indicates that nearly 85 percent of clinical trials experience delays, more than half require protocol amendments, and close to one-third terminate early, often because of avoidable design and recruitment challenges. Each protocol amendment can cost more than $500,000 and extend study timelines by several months.

Clintelligence seeks to address these issues by using artificial intelligence to analyze a large database of “historical clinical trials, delivering predictive insights that help sponsors avoid common pitfalls before a trial begins.” According to the company, the platform has demonstrated up to 85 percent accuracy in predicting trial risks and can generate average savings of approximately $350,000 per study.

“30% of clinical trials fail predictably and 85% are delayed–but those failures and delays are often preventable,” said Agam Bansal. “Our mission at Clintelligence is to use the power of AI to learn from historical trials’ outcomes data and avoid costly mistakes. Jeeva Clinical is a perfect platform to incorporate actionable trial intelligence across the drug development lifecycle.”

The statement added that Clintelligence enables sponsors to evaluate draft protocols using patterns derived from more than one million past studies. The platform can predict the likelihood of amendments, enrollment delays, and trial termination risks, while also offering recommendations to simplify eligibility criteria, refine endpoints, and improve operational feasibility.

“By integrating these insights with Jeeva’s rapid protocol configuration capabilities, sponsors can move into study setup with optimized protocols, reducing downstream amendments, accelerating timelines, and improving overall trial outcomes,” the statement said.